Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...

Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are ...

A larger diameter of the main pulmonary artery predicts poorer outcomes in pulmonary arterial hypertension (PAH) patients, a ...

Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...

Back to Healio In this episode, we dive into the early therapies and how our understanding of vascular physiology drastically changed the management of pulmonary hypertension.

Highlight box Key findings • The bibliometric analysis summarized the major areas and promising research directions on chronic thromboembolic pulmonary hypertension (CTEPH) over the past two decades.

A new program in the Central Valley is now offering much-needed treatments for patients suffering from an advanced form of lung disease called pulmonary ...